Plunkett Research Online: argenx SE

ARGENX SE (ARGX:NAS) Company Profile, Corporate Revenues, Growth, Market Size, Analysis, Business Forecasts, Market Share, Metrics, SWOT

argenx SE is an immunology company. It is engaged in the business of developing a pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer. The group has partnered with academic researchers through its Immunology Innovation Program (IIP) and aims.....



argenx SE
Ticker: ARGX
Exchange: NAS
Parent Company:
Year Established:
Employees:
Fiscal Year Ends in

Phone: 31 763030488
Fax:
Address: Laarderhoogtweg 25
Amsterdam, NH 1101EB Netherlands

Map
Types Of Business
Industry Ranks

Industry NAICS code:

Pharmaceuticals, Biopharmaceuticals, Generics and Drug Manufacturing
Contacts Description
Tim HauwermeirenCEO/Co-Founder/Director
Karl GubitzCFO
See More
argenx SE is an immunology company. It is engaged in the business of developing a pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer. The group has partnered with academic researchers through its Immunology Innovation Program (IIP) and aims.....See More See More

Auditor: Deloitte Accountants B.V.
Legal Advisor:
$USD, In whole numbers,
except marked * or %
202320222021202020192018
Financials
    Revenue
    Cost of Revenue
    Gross Margin %
    R&D Expense
    Operating Income
    Operating Margin %
    SGA Expense
    Net Income
    Earnings Per Share
    Dividends
    Book Value Per Share
    Operating Cash Flow
    Capital Expenditure
    Free Cash Flow
Profitability
    EBITDA
    Return on Assets %
    Return on Equity %
    Net Margin %
    Assets Turnover
    Financial Leverage
Brands, Divisions and Affiliates Top Salaries
NameTitleSalary (US$)Bonus (US$)
Other Thoughts Corporate Culture

Apparent Female Officers or Directors: